MX390860B - Composiciones adyuvantes y metodos relacionados. - Google Patents

Composiciones adyuvantes y metodos relacionados.

Info

Publication number
MX390860B
MX390860B MX2017012220A MX2017012220A MX390860B MX 390860 B MX390860 B MX 390860B MX 2017012220 A MX2017012220 A MX 2017012220A MX 2017012220 A MX2017012220 A MX 2017012220A MX 390860 B MX390860 B MX 390860B
Authority
MX
Mexico
Prior art keywords
present disclosure
related methods
composition
adjuvant compositions
adjuvant composition
Prior art date
Application number
MX2017012220A
Other languages
English (en)
Other versions
MX2017012220A (es
Inventor
Mary Ann Pfannenstiel
Timothy J Miller
Original Assignee
Huvepharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huvepharma Inc filed Critical Huvepharma Inc
Publication of MX2017012220A publication Critical patent/MX2017012220A/es
Publication of MX390860B publication Critical patent/MX390860B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una composición inmunogéncia caracterizada porque comprende: a. una composición adyuvante que comprende: i. un lipófilo: y ii.un polímero de ácido acrílico o metacrílico; y b. un antígeno, en donde el antígeno es ADN competente no replicativo en donde el adyuvante no comprende Ca++, cationes divalente o vehículos liposómicos derivados de cationes divalentes.
MX2017012220A 2015-03-24 2016-03-24 Composiciones adyuvantes y metodos relacionados. MX390860B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562137659P 2015-03-24 2015-03-24
PCT/US2016/024003 WO2016154432A1 (en) 2015-03-24 2016-03-24 Adjuvant compositions and related methods

Publications (2)

Publication Number Publication Date
MX2017012220A MX2017012220A (es) 2018-02-09
MX390860B true MX390860B (es) 2025-03-21

Family

ID=56973861

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012220A MX390860B (es) 2015-03-24 2016-03-24 Composiciones adyuvantes y metodos relacionados.

Country Status (7)

Country Link
US (2) US9636397B2 (es)
EP (1) EP3273950A4 (es)
JP (1) JP6925277B2 (es)
AU (1) AU2016235059B2 (es)
CA (1) CA2979556C (es)
MX (1) MX390860B (es)
WO (1) WO2016154432A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195261B2 (en) * 2014-11-26 2019-02-05 VaxLiant, LLC Adjuvant compositions and related methods
MX390860B (es) * 2015-03-24 2025-03-21 Huvepharma Inc Composiciones adyuvantes y metodos relacionados.
GB201616904D0 (en) * 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
US11197928B2 (en) 2017-01-13 2021-12-14 Board Of Regents, The University Of Texas System Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
CA3064475A1 (en) 2017-05-31 2018-12-06 Texas Tech University System Methods and devices for the treatment of food allergies
BR112020013405A2 (pt) 2018-01-25 2020-12-01 Acm Biolabs Pte Ltd. polimerossomas compreendendo um antígeno encapsulado solúvel, assim como métodos de sua fabricação e uso
US11813321B2 (en) * 2018-07-13 2023-11-14 Biomune Company Vaccines against avian reoviruses
EP3849600A1 (en) 2018-09-12 2021-07-21 ACM Biolabs Pte Ltd Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
CA3143533A1 (en) 2019-08-01 2021-02-04 Madhavan Nallani A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersome
AU2021260857A1 (en) 2020-04-24 2022-11-03 Acm Biolabs Pte Ltd Vaccine against human-pathogenic coronaviruses
EP4175666A1 (en) * 2020-07-03 2023-05-10 Statens Serum Institut A dna plasmid sars-coronavirus-2/covid-19 vaccine
EP4259197A1 (en) 2020-12-11 2023-10-18 ACM Biolabs Pte Ltd Modulating th1/th2 immune response by administering two populations of polymersomes having an associated antigen and an associated adjuvant
US20240108720A1 (en) 2021-02-02 2024-04-04 Acm Biolabs Pte Ltd Sole use of polymersome associated adjuvant for stimulating an immune response
EP4322922A1 (en) 2021-04-12 2024-02-21 ACM Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
CN113913395B (zh) * 2021-10-19 2022-06-14 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 人工重组的h5n8流感病毒及其制备方法和应用
EP4482477A1 (en) 2022-02-23 2025-01-01 ACM Biolabs Pte Ltd Polymer-lipid hybrid nanoparticles comprising a lipid and a block copolymer as well as methods of making and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US20080292663A1 (en) * 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines
CN102076358B (zh) * 2008-06-27 2016-08-17 硕腾有限责任公司 新颖的佐剂组合物
EP2306975A4 (en) * 2008-07-21 2012-10-31 Otonomy Inc COMPOSITIONS WITH A TAXED RELEASE FOR MODULATING THE EARM STRUCTURE AND THE BORN IMMUNE SYSTEM, AND METHODS OF TREATING EAR OR DISEASE
US20110207952A1 (en) * 2010-02-22 2011-08-25 Rafael Avila Cholesterol extraction from algae and preparation of vegan vitamin d3
EP4218808A3 (en) * 2012-03-12 2023-08-09 Advanced BioAdjuvants, LLC Adjuvant and vaccine compositions
MX363017B (es) 2012-11-01 2019-03-04 Factor Bioscience Inc Métodos y productos para la expresión de proteínas en células.
US10195261B2 (en) 2014-11-26 2019-02-05 VaxLiant, LLC Adjuvant compositions and related methods
MX388527B (es) * 2014-11-26 2025-03-20 Huvepharma Inc Composiciones adyuvantes y metodos relacionados.
MX390860B (es) * 2015-03-24 2025-03-21 Huvepharma Inc Composiciones adyuvantes y metodos relacionados.

Also Published As

Publication number Publication date
EP3273950A1 (en) 2018-01-31
MX2017012220A (es) 2018-02-09
CA2979556C (en) 2023-07-18
CA2979556A1 (en) 2016-09-29
US10265395B2 (en) 2019-04-23
US9636397B2 (en) 2017-05-02
AU2016235059B2 (en) 2021-04-01
AU2016235059A1 (en) 2017-10-05
US20160279237A1 (en) 2016-09-29
JP2018510874A (ja) 2018-04-19
WO2016154432A1 (en) 2016-09-29
NZ735525A (en) 2024-05-31
JP6925277B2 (ja) 2021-08-25
BR112017020175A2 (pt) 2018-06-12
EP3273950A4 (en) 2019-04-24
US20170202959A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
MX390860B (es) Composiciones adyuvantes y metodos relacionados.
CY1125368T1 (el) Εμβολια κατα των ιων του αναπνευστικου συστηματος
BR112018008090A2 (pt) vacina de vírus do herpes simplex.
BR112018008102A2 (pt) vacina de vírus sincicial respiratório
MX2018004916A (es) Vacuna contra el virus de la influenza de amplio espectro.
EA201790398A1 (ru) Способы лечения заболевания печени
EP3012322A4 (en) GENEELED STRAIN VARIANT OF PORCINE PSEUDORABIES VIRUS, VACCINE COMPOSITION, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF
BR112018012873A2 (pt) vacina de vírus zika
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
CL2016002679A1 (es) Métodos para mejorar o acelerar la recuperación física después la cirugía por fractura de cadera.
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
EP4324473A3 (en) Multiparametric nucleic acid optimization
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
TW201613556A (en) Swine virus vaccines that are liquid stable
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
MX2017003121A (es) Formulaciones de anticuerpos.
BR112017025705A2 (pt) método de liberação de glicosídeos de esteviol de uma célula hospedeira, método de recuperação de glicosídeos de esteviol de uma composição e composição
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
MX381211B (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
BR112017003462A2 (pt) coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
MX388527B (es) Composiciones adyuvantes y metodos relacionados.